Lisata Therapeutics Inc

BRIEF

published on 04/01/2025 at 15:36, 1 day 11 hours ago

Lisata Therapeutics Inc Announces Positive FY/24 Results

Lisata Therapeutics Certepetide FY/24 Results Cancer Studies GATC Health Collaboration
PRESS RELEASE

published on 04/01/2025 at 15:31, 1 day 11 hours ago

Original-Research: Lisata Therapeutics Inc (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research updates Lisata Therapeutics Inc (ISIN: US1280583022) research with a Buy recommendation and USD 15.00 target price. Lisata's FY/24 results exceeded expectations, with promising developments in certepetide trials and AI collaboration

First Berlin Equity Research Buy Recommendation Research Update Certepetide Lisata Therapeutics Inc
BRIEF

published on 01/29/2025 at 09:56, 2 months 4 days ago

Lisata Therapeutics: Promising Preliminary Results and Buy Recommendation

Buy Recommendation Lisata Therapeutics Certepetide ASCEND Trial PDAC Treatment
PRESS RELEASE

published on 01/29/2025 at 09:51, 2 months 4 days ago

Original-Research: Lisata Therapeutics Inc (von First Berlin Equity Research GmbH): BUY
First Berlin Equity Research reaffirms BUY rating for Lisata Therapeutics Inc with USD 15.00 target price. Encouraging results for certepetide in pancreatic cancer treatment. Analyst: Christian Orquera

Investment Pancreatic Cancer Christian Orquera Lisata Therapeutics Certepetide
BRIEF

published on 01/21/2025 at 14:01, 2 months 12 days ago

First Berlin Initiates Buy Rating on Lisata Therapeutics

Clinical Trials BUY Rating Lisata Therapeutics Certepetide Qilu Pharmaceuticals
PRESS RELEASE

published on 01/21/2025 at 13:56, 2 months 12 days ago

Original-Research: Lisata Therapeutics Inc (von First Berlin Equity Research GmbH): BUY
First Berlin Equity Research initiates coverage on Lisata Therapeutics Inc, a US pharmaceutical company focusing on innovative therapies for solid tumors. Analyst recommends BUY with USD15.00 target price

Pharmaceutical Company First Berlin Equity Research Solid Tumors Innovative Therapies Lisata Therapeutics Inc

Published on 04/03/2025 at 01:35, 1 hour 30 minutes ago

GMV Minerals Inc. Closes Non-Brokered Financing/ Engages Investor Relations Firm
Published on 04/02/2025 at 23:35, 3 hours 30 minutes ago

Murchison Minerals to Seek Shareholders’ Approval for Share Consolidation
Published on 04/02/2025 at 20:00, 7 hours 5 minutes ago

Network-1 Announces Acquisition of Patent Portfolio
Published on 04/02/2025 at 17:25, 9 hours 40 minutes ago

SOBRsafe Announces Reverse Stock Split
Published on 04/02/2025 at 15:00, 12 hours 5 minutes ago

Doubleview Gold Corp 2025 Exploration Program

View all ACCESSWIRE

Published on 04/02/2025 at 20:20, 6 hours 44 minutes ago

EQS-Adhoc: Siemens Aktiengesellschaft: Siemens acquires Dotmatics to extend AI-powered software portfolio to Life Sciences
Published on 04/02/2025 at 20:01, 7 hours 4 minutes ago

Annual General Meeting of Deutsche Konsum REIT-AG successfully held
Published on 04/02/2025 at 20:01, 7 hours 4 minutes ago

Travis Perkins: Publication of the Annual Report and Accounts 2024
Published on 04/02/2025 at 19:40, 7 hours 24 minutes ago

LION E-Mobility AG starts successfully into the new 2025 financial year – Challenging market environment impacts 2024
Published on 04/02/2025 at 19:13, 7 hours 52 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares

View all EQS

Published on 04/03/2025 at 00:37, 2 hours 28 minutes ago

Publication of the report on payments made to governments provided by article L.225-102-3 of the French Commercial Code
Published on 04/02/2025 at 18:05, 9 hours ago

Financial statements - 31 december 2024
Published on 04/02/2025 at 17:45, 9 hours 20 minutes ago

Aéroports de Paris SA - Voting rights as of 31 March 2025
Published on 04/02/2025 at 17:45, 9 hours 20 minutes ago

Availability of the Pre-Q1 2025 Sales Communication
Published on 04/02/2025 at 17:45, 9 hours 20 minutes ago

Information concerning the total number of voting rights and shares 2025 03 31

View all LES ECHOS COMFI WIRE

News